We have drugged 30 targets in the immune synapse with novel, fully human monoclonal antibodies. Our pipeline includes a growing set of therapeutic candidates against cell surface and soluble immune targets built from our integrated antibody discovery and protein engineering platform. Our platform enables the identification of unique epitopes and distinct combinations of biologics on an unprecedented scope and scale.
COMPASS INTEGRATED PLATFORM
Our platform has several distinct advantages, including the generation of highly diverse antibody sets, novel biological screening techniques, the ability to interrogate multispecific antibodies, and speed, all of which enable rapid discovery of high-quality antibody therapeutics. Currently, our robust antibody discovery platform is capable of drugging 2 new targets per month.
OUR CURRENT PIPELINE OF IMMUNO-ONCOLOGY AND AUTOIMMUNE PROGRAMS